Evolent Health Inc (NYSE:EVH)’s traded shares stood at 1.68 million during the last session, with the company’s beta value hitting 1.18. At the close of trading, the stock’s price was $9.96, to imply a decrease of -1.29% or -$0.13 in intraday trading. The EVH share’s 52-week high remains $33.63, putting it -237.65% down since that peak but still an impressive 16.16% since price per share fell to its 52-week low of $8.35. The company has a valuation of $1.16B, with an average of 2.73 million shares in intraday trading volume over the past 10 days and average of 2.47 million shares over the past 3 months.
Analysts have given a consensus recommendation of Buy for Evolent Health Inc (EVH), translating to a mean rating of 1.13. Of 5 analyst(s) looking at the stock, 0 analyst(s) give EVH a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 5 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at 0.09.
Evolent Health Inc (NYSE:EVH) trade information
After registering a -1.29% downside in the last session, Evolent Health Inc (EVH) has traded red over the past five days. The 5-day price performance for the stock is 4.40%, and -5.32% over 30 days. With these gigs, the year-to-date price performance is -11.47%. Short interest in Evolent Health Inc (NYSE:EVH) saw shorts transact 14.2 million shares and set a 5.68 days time to cover.
The extremes give us $14 and $38 for target low and target high price respectively. As such, EVH has been trading -281.53% off suggested target high and -40.56% from its likely low.
Evolent Health Inc (EVH) estimates and forecasts
The rating firms project that company’s revenue will shrink -19.00% compared to the previous financial year.
Revenue forecast for the current quarter as set by 14 analysts is 460.15M. Meanwhile, for the current quarter, a total of 14 analyst(s) estimate revenue growth to 503.6M.Earnings reports from the last fiscal year show that sales brought in 639.65M and 647.14M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to fall -28.06% before dropping -22.18% in the following quarter.
An assessment of the company’s 5-year growth patterns shows that annual earnings grew an estimated 25.98% for the past 5-year period. While 2025 is set for a 4.08% return in earnings, projections for the next 5 years are at 28.63% annually.
EVH Dividends
Evolent Health Inc has its next earnings report out on 2025-Feb-19. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
Evolent Health Inc (NYSE:EVH)’s Major holders
Evolent Health Inc insiders hold 2.71% of total outstanding shares, with institutional holders owning 107.42% of the shares at 110.41% float percentage. In total, 107.42% institutions holds shares in the company, led by WELLINGTON MANAGEMENT GROUP LLP. As of 2024-06-30, the company held over 11.17 million shares (or 9.7383% of shares), all amounting to roughly $213.55 million.
The next major institution holding the largest number of shares is VANGUARD GROUP INC with 11.06 million shares, or about 9.6862% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $211.39 million.
We also have Vanguard Health Care Fund and Fidelity Small Cap Value Fund as the top two Mutual Funds with the largest holdings of the Evolent Health Inc (EVH) shares. Going by data provided on Oct 31, 2024 , Vanguard Health Care Fund holds roughly 4.98 shares. This is just over 4.27% of the total shares, with a market valuation of $49.57 million. Data from the same date shows that the other fund manager holds a little less at 4.47, or 3.83% of the shares, all valued at about 44.51 million.
